Biotech major, Biocon, has announced that its results were positive for treat –plaq study with Itolizumab in chronic plaque psoriasis (skin related disease).
The company in a release said its double blind, placebo controlled, phase III treat –Plaq study of the first humanised anti CD-6 monoclonal antibody, successfully met the pre-specified primary end-point of significant improvement in PASI-75 (Psoriasis Area and Severity Index) score after 12 weeks of treatment in patients with moderate to severe psoriasis compared to placebo. It also met multiple secondary end-points after 12 and 28 weeks of treatment.
Commenting on the development, Ms. Kiran Mazumdar-Shaw, Chairman & Managing Director, Biocon, “Itolizumab represents a significant advancement in the treatment of psoriasis and potentially other autoimmune diseases with an excellent risk-benefit profile.”
This could possibly become the first novel biologic developed and approved from India and is an important milestone for Biocon in its pursuit of affordable innovation.
“We look forward to taking this molecule to the market across multiple indications with a global partner to ensure that affordable innovation reaches patients worldwide in a timely manner,” she added.